工业工程 ›› 2015, Vol. 18 ›› Issue (5): 115-121.

• 专题论述 • 上一篇    下一篇

基于DEA-Tobit的创新型医药生物企业创新效率

  

  1. (华南理工大学 工商管理学院,广东 广州 510641)
  • 出版日期:2015-10-31 发布日期:2016-03-24
  • 作者简介:唐勇(1970-),男,云南省人,博士研究生,主要研究方向为技术创新、组织学习及国际企业管理。
  • 基金资助:

    广东省软科学资助项目 (2012B070300039, 2009B080701027);广东省知识产权局软科学研究计划资助项目 (GD2P2012-K01)

A DEA-Tobit based Analysis of the Innovation Efficiency of-Pharmaceutical and Biological Innovative Enterprises

  1. (School of Business Administration,South China University of Technology,Guangzhou 510641,China)
  • Online:2015-10-31 Published:2016-03-24

摘要: 利用DEA-Tobit两步法对中小板上市的创新型医药生物企业先测算了创新效率,进一步探讨了创新支持政策对创新效率的影响。实证研究表明,大部分企业技术效率不高,纯技术效率有提高,规模效率未达到有效;高强度的政府补贴提高了企业的纯技术效率;税费返还则对纯技术效率有负向影响;创新平台显著提高了技术效率和规模效率。

关键词: 创新型企业, 创新效率, DEAEBM模型, Tobit回归, 创新政策, 创新平台

Abstract: As innovative enterprises are important carriers of innovationdriven development strategy in China, innovation platforms can effectively stimulate innovation activities. SME Board pharmaceutical and biotech innovative companies are set as samples and the innovative efficiency is assessed with a DEATobit twostep model. The impact of innovation support policy on innovation efficiency is also discussed. An empirical study shows that most of the enterprises have low technical efficiency. Though the pure technical efficiency has improved, the scale efficiency is still low. What's more, though high strength of government subsidies improves their pure technical efficiency, tax return has negative influence on it. Innovation platforms improve both technical and scale efficiency. Thus, five suggestions are made based on our study.

Key words: innovative companies, innovation efficiency, DEAEBM model, Tobit regression, innovation policy, innovation platfor